222 related articles for article (PubMed ID: 34649203)
21. Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia.
Larance B; Degenhardt L; Grebely J; Nielsen S; Bruno R; Dietze P; Lancaster K; Larney S; Santo T; Shanahan M; Memedovic S; Ali R; Farrell M
Addiction; 2020 Jul; 115(7):1295-1305. PubMed ID: 31860767
[TBL] [Abstract][Full Text] [Related]
22. Using administrative data to predict cessation risk and identify novel predictors among new entrants to opioid agonist treatment.
Bharat C; Degenhardt L; Dobbins T; Larney S; Farrell M; Barbieri S
Drug Alcohol Depend; 2021 Nov; 228():109091. PubMed ID: 34592705
[TBL] [Abstract][Full Text] [Related]
23. A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia.
Burns L; Gisev N; Larney S; Dobbins T; Gibson A; Kimber J; Larance B; Mattick RP; Butler T; Degenhardt L
Addiction; 2015 Apr; 110(4):646-55. PubMed ID: 25516077
[TBL] [Abstract][Full Text] [Related]
24. Supervised dosing with a long-acting opioid medication in the management of opioid dependence.
Saulle R; Vecchi S; Gowing L
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD011983. PubMed ID: 28447766
[TBL] [Abstract][Full Text] [Related]
25. Relationship between choice of opioid agonist therapy and distance from patients' residences in Taiwan, 2012-2014.
Wei LC; Chan HY
Am J Drug Alcohol Abuse; 2021 Sep; 47(5):590-598. PubMed ID: 34402338
[TBL] [Abstract][Full Text] [Related]
26. Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone.
Rolland B; Trojak B; Nourredine M; Bachellier J; Chappuy M; Bendimerad P; Kosim M; Hjelmström P; Meroueh F; Nubukpo P; Brousse G
Drug Alcohol Depend; 2021 Mar; 220():108492. PubMed ID: 33482572
[TBL] [Abstract][Full Text] [Related]
27. The impact of community pharmacy dispensing fees on the introduction of buprenorphine - naloxone in Australia.
Winstock AR; Lea T; Ritter A
Drug Alcohol Rev; 2007 Jul; 26(4):411-6. PubMed ID: 17564877
[TBL] [Abstract][Full Text] [Related]
28. A latent class analysis of self-reported clinical indicators of psychosocial stability and adherence among opioid substitution therapy patients: do stable patients receive more unsupervised doses?
Larance B; Carragher N; Mattick RP; Lintzeris N; Ali R; Degenhardt L
Drug Alcohol Depend; 2014 Sep; 142():46-55. PubMed ID: 25015687
[TBL] [Abstract][Full Text] [Related]
29. Administration and patient-incurred costs associated with opioid agonist treatment in Norway.
Pedersen MH; Danø A; Gibbons C; Jensen R
Curr Med Res Opin; 2022 Nov; 38(11):1959-1965. PubMed ID: 36172758
[TBL] [Abstract][Full Text] [Related]
30. Retention of opioid agonist treatment prescribers across New South Wales, Australia, 2001-2018: Implications for treatment systems and potential impact on client outcomes.
Jones NR; Nielsen S; Farrell M; Ali R; Gill A; Larney S; Degenhardt L
Drug Alcohol Depend; 2021 Feb; 219():108464. PubMed ID: 33360851
[TBL] [Abstract][Full Text] [Related]
31. Trends in Out-of-Pocket Costs for and Characteristics of Pharmacy-Dispensed Buprenorphine Medications for Opioid Use Disorder Treatment by Type of Payer, 2015 to 2020.
Strahan AE; Desai S; Zhang K; Guy GP
JAMA Netw Open; 2023 Feb; 6(2):e2254590. PubMed ID: 36763363
[TBL] [Abstract][Full Text] [Related]
32. Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence: A Systematic Review and Meta-analysis.
Santo T; Clark B; Hickman M; Grebely J; Campbell G; Sordo L; Chen A; Tran LT; Bharat C; Padmanathan P; Cousins G; Dupouy J; Kelty E; Muga R; Nosyk B; Min J; Pavarin R; Farrell M; Degenhardt L
JAMA Psychiatry; 2021 Sep; 78(9):979-993. PubMed ID: 34076676
[TBL] [Abstract][Full Text] [Related]
33. Assessing the determinants of completing OAT induction and long-term retention: A population-based study in British Columbia, Canada.
Kurz M; Min JE; Dale LM; Nosyk B
J Subst Abuse Treat; 2022 Feb; 133():108647. PubMed ID: 34740484
[TBL] [Abstract][Full Text] [Related]
34. Management of opioid-dependent patients: comparison of the cost associated with use of buprenorphine/naloxone or methadone, and their interactions with concomitant treatments for infectious or psychiatric comorbidities.
Roncero C; Domínguez-Hernández R; Díaz T; Fernández JM; Forcada R; Martínez JM; Seijo P; Terán A; Oyagüez I
Adicciones; 2015 Sep; 27(3):179-89. PubMed ID: 26437312
[TBL] [Abstract][Full Text] [Related]
35. The effect of entry and retention in opioid agonist treatment on contact with the criminal justice system among opioid-dependent people: a retrospective cohort study.
Gisev N; Bharat C; Larney S; Dobbins T; Weatherburn D; Hickman M; Farrell M; Degenhardt L
Lancet Public Health; 2019 Jul; 4(7):e334-e342. PubMed ID: 31201133
[TBL] [Abstract][Full Text] [Related]
36. Quality of primary care among individuals receiving treatment for opioid use disorder.
Spithoff S; Kiran T; Khuu W; Kahan M; Guan Q; Tadrous M; Leece P; Martins D; Gomes T
Can Fam Physician; 2019 May; 65(5):343-351. PubMed ID: 31088874
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of expanding the capacity of opioid agonist treatment in Ukraine: dynamic modeling analysis.
Morozova O; Crawford FW; Cohen T; Paltiel AD; Altice FL
Addiction; 2020 Mar; 115(3):437-450. PubMed ID: 31478285
[TBL] [Abstract][Full Text] [Related]
38. Primary healthcare-based integrated care with opioid agonist treatment: First experience from Ukraine.
Morozova O; Dvoriak S; Pykalo I; Altice FL
Drug Alcohol Depend; 2017 Apr; 173():132-138. PubMed ID: 28242537
[TBL] [Abstract][Full Text] [Related]
39. Is use of opioid agonist treatment associated with broader primary healthcare use among men with recent injecting drug use histories following release from prison? A prospective cohort study.
Curtis M; Wilkinson AL; Dietze P; Stewart AC; Kinner SA; Winter RJ; Aitken C; Walker SJ; Cossar RD; Butler T; Stoové M
Harm Reduct J; 2023 Mar; 20(1):42. PubMed ID: 36978089
[TBL] [Abstract][Full Text] [Related]
40. Opioid agonist treatment (OAT) experiences and release plans among federally incarcerated individuals with opioid use disorder (OUD) in Ontario, Canada: a mixed-methods study.
Russell C; Nafeh F; Pang M; MacDonald SF; Derkzen D; Rehm J; Fischer B
BMC Public Health; 2022 Mar; 22(1):436. PubMed ID: 35246083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
